Optimum fractionation of radiation to combine PD‐1 blockade

Abstract The optimum fractionation of radiation to combine with immune checkpoint blockade is controversial. This study aimed to investigate the fractionated radiation to maximize immunity during combination therapy. To evaluate the abscopal effect, C57BL/6 hPD‐1 knock‐in mice bearing two syngeneic contralateral MC38 murine colon cancer tumors were treated with four distinct regimens of radiotherapy. Three fractions of 8 Gy were chosen as the optimal fractionation to combine with anti‐PD‐1 as the optimal fractionation for maximizing immunity. Anti‐PD‐1 administration enhanced both local and systemic antitumor immunity in a cytotoxic T cell–dependent manner. Meanwhile, the spleen exhibited decreased myeloid‐derived suppressor cells (MDSCs) under combination treatment. Furthermore, RNA‐sequencing revealed significantly increased tumor necrosis factor (TNF) receptors and cytokines associated with lymphocyte infiltration in the combining group. Here we demonstrate that the hypofractionation of 8 Gy × 3f was the optimum‐fractionated dosage to maximize immunity, and the combination of anti‐PD‐1 showed promising results in boosting abscopal effect. Underlying mechanisms may include the activation of T cells and the reduction of MDSCs, which is achieved through the action of TNF and related cytokines. This study indicates a radioimmunotherapy dosage painting method that can be developed to overcome present limitations in tumor immunosuppression.

[1]  F. Teng,et al.  Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma. , 2022, International immunopharmacology.

[2]  Jinming Yu,et al.  The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects? , 2021, Biomarker research.

[3]  Zhaofei Liu,et al.  ICAM-1 orchestrates the abscopal effect of tumor radiotherapy , 2021, Proceedings of the National Academy of Sciences.

[4]  L. Galluzzi,et al.  Immunological impact of cell death signaling driven by radiation on the tumor microenvironment , 2019, Nature Immunology.

[5]  N. Datta,et al.  Efficacy and Safety Evaluation of the Various Therapeutic Options in Locally Advanced Cervix Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. , 2019, International journal of radiation oncology, biology, physics.

[6]  Betty Y. S. Kim,et al.  The Reciprocity between Radiotherapy and Cancer Immunotherapy , 2018, Clinical Cancer Research.

[7]  Joe Y. Chang,et al.  Time to abandon single-site irradiation for inducing abscopal effects , 2018, Nature Reviews Clinical Oncology.

[8]  K. McDonald,et al.  Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis , 2018, Journal of Neuro-Oncology.

[9]  Jinming Yu,et al.  Abscopal effect of radiotherapy combined with immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.

[10]  S. Demaria,et al.  Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. , 2018, Trends in immunology.

[11]  Yuquan Wei,et al.  Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. , 2018, International journal of radiation oncology, biology, physics.

[12]  J. Hesser,et al.  Using immunotherapy to boost the abscopal effect , 2018, Nature Reviews Cancer.

[13]  J. Wargo,et al.  Immunotherapy resistance: the answers lie ahead – not in front – of us , 2017, Journal of Immunotherapy for Cancer.

[14]  J. Lee,et al.  Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.

[15]  Jinming Yu,et al.  Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. , 2015, Translational research : the journal of laboratory and clinical medicine.

[16]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[17]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures in cancer and beyond. , 2014, Trends in immunology.

[18]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[19]  Pierre Validire,et al.  Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. , 2014, Cancer research.

[20]  Stephen Mok,et al.  CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.

[21]  M. Sade-Feldman,et al.  Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. , 2013, Immunity.

[22]  M. Suárez-Fariñas,et al.  Gene profiling of narrowband UVB-induced skin injury defines cellular and molecular innate immune responses. , 2013, The Journal of investigative dermatology.

[23]  U. Syrbe,et al.  TNF signaling drives myeloid-derived suppressor cell accumulation. , 2012, The Journal of clinical investigation.

[24]  K. Iwamoto,et al.  Maximizing tumor immunity with fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.

[25]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[26]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[27]  S. Siva,et al.  Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[29]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[30]  E. Tartour,et al.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Pardoll,et al.  Cancer immunotherapy: breaking the barriers to harvest the crop , 2004, Nature Medicine.

[32]  N. Kawashima,et al.  Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.

[33]  L. Peters,et al.  Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. , 1979, Journal of the National Cancer Institute.

[34]  H. Suit,et al.  Immunologic status of host and response of a methylcholanthrene‐induced sarcoma to local x‐irradiation , 1970, Cancer.

[35]  S. Gettinger,et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.

[36]  P. Venkat,et al.  Systematic review of case reports on the abscopal effect. , 2016, Current problems in cancer.